Treatment Center Directory

Spectator couple hero image
Spectator couple hero image
Hero Treatment Center Directory

Treatment Center Directory

Search the AMVUTTRA® Treatment Center Directory to locate the treatment center closest to your patient

Treatment Center Directory

Search the AMVUTTRA® Treatment Center Directory to locate the treatment center closest to your patient

 
 

The AMVUTTRA Treatment Center Directory is for informational purposes only. No fees or other remuneration have been or will be exchanged for a treatment center’s inclusion in this database. Inclusion of centers in this database will be based on opt-in approval by authorized personnel for those sites listed. Inclusion in this database does not represent an endorsement of, recommendation for, or referral to the treatment centers listed in this database by Alnylam Pharmaceuticals. Likewise, participating treatment centers do not necessarily administer or endorse any Alnylam products.

To find other treatment centers near your patient, try using the National Infusion Center Association (NICA) Locator.

Interested in being listed in the AMVUTTRA Online Treatment Center Directory?
 
Register now

Update or remove your contact information from this directory.

Important Safety Information and Indication

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA® (vutrisiran) treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

Indication

AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.